Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
2021 Third quarter results announcement
We will announce our third quarter 2021 results at 12:00 BST, 07:00 EDT on Wednesday 27 October.
Following the announcement there will be a webcast hosted by Emma Walmsley, CEO, and other members of CET at 14:00 BST, 09:00 EDT.
New GSK Investor update
Emma Walmsley, CEO, and other members of CET hosted a virtual investor update on Wednesday 23 June.
The update provided a clear view of the strategy for New GSK, its outlook for growth and the opportunities we see for shareholder value creation.
Nick Stone appointed SVP Head of Investor Relations
Nick Stone has been appointed Head of Investor Relations, effective 4 October 2021.
Nick joins from AstraZeneca, where he has been leading Investor Relations in Europe, the Americas, and Asia Pacific, along with the sustainability outreach programme. Prior to this, he spent fifteen years in the biopharmaceutical sector, including in the areas of Commercial, Business Development and Corporate Strategy.
A qualified lawyer, Nick will lead IR for New GSK, working closely with the Consumer Healthcare IR team under Sonya Ghobrial in the run-up to the planned separation in mid-2022.
Latest information
Latest press releases
- GSK unveils plan for UK headquarters of new Consumer Healthcare company
- GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine
- ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV
Annual Report 2020
We published our Annual Report 2020 on 09 March 2021. View the summary and download the full report or individual sections.
Sign up for announcements
Sign up to receive email notifications when we publish a stock exchange announcement.